

11 July 2011

## 2011/12 Invitation to Tender

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply;
- The draft process and terms and conditions for the 2011/12 Invitation to Tender (2011/12 Tender); and
- Commercial proposals as an alternative to tendering.

PHARMAC welcomes all feedback on the draft 2011/12 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or Chief Executive acting under Delegated Authority) prior to making a decision on this proposal.

Feedback should be submitted by the following dates; late feedback may not be considered:

**ALTERNATIVE COMMERCIAL PROPOSAL RESPONSES DUE BY  
5 PM, FRIDAY 5 AUGUST 2011**

**ALL OTHER CONSULTATION RESPONSES DUE BY  
5 PM, FRIDAY 19 AUGUST 2011**

Feedback should be provided by submitting an email, fax or letter to:

Kyle Reid  
Tender Analyst  
PHARMAC  
PO Box 10-254  
Wellington 6143

Email: [kyle.reid@pharmac.govt.nz](mailto:kyle.reid@pharmac.govt.nz)

Fax: (04) 460 4995  
DDI: (04) 916 7556

### Details of the proposed 2011/12 Tender

In general, the proposed 2011/12 Tender process would be similar to the 2010/11 Tender. In addition to Alternative Commercial Proposals (discussed later), we seek comments on all sections of the draft 2011/12 Tender, in particular on:

- The proposed tender process and timelines, including discussion on the impact of the new tender timelines which were implemented in the 2010/11 Tender;
- The proposed changes to the 2011/12 Tender;
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2011/12 Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered;

- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2011/12 Tender, that you consider would be inappropriate to tender, and the reasons for that view, including any contractual constraints or patent protection that could restrict PHARMAC from awarding a tender on a particular pharmaceutical;
- For Hospital Pharmaceuticals, feedback on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event that a 1% Discretionary Variance Limit is not considered clinically acceptable; and
- Feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance.

### **Draft Invitation to Tender**

We are seeking feedback on the composition of the draft 2011/12 Tender. This is still under development and may change before it is taken to the Board for approval and subsequently issued. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out further drafts for consultation.

A complete copy of the draft 2011/12 Tender, including the proposed terms and conditions which successful tender bids would be subject to, is available on our website ([www.pharmac.govt.nz](http://www.pharmac.govt.nz)). The draft 2011/12 Tender comprises the following sections:

- Schedule 1: Definitions and interpretation
- Schedule 2: The list of pharmaceuticals proposed for tender\* #
- Schedule 3: The Tender process (for both hospital and community Tenders)
- Schedule 4: Contract terms for Sole Subsidised Supply and/or Hospital Supply Status
- Schedule 5: Additional contract terms for Sole Subsidised Supply Status
- Schedule 6: Additional contract terms for Hospital Supply Status

\* The market data for the year ended 30 June 2011 provided in Schedule Two has not yet been finalised and is partially based on forecasts; however, finalised data would be included in the final 2011/12 Tender. The figures included are indicative only and are provided on the basis set out in clause 1.3 of Schedule 2 of the draft 2011/12 Tender.

# The final list of products, which may change following consultation, would be released as part of the 2011/12 Tender, following Board approval. You may provide feedback on the inclusion of any additional pharmaceuticals after the 2011/12 Tender has been issued, and any such feedback would be considered by the Board (or Chief Executive under Delegated Authority) before making a final decision on any product, provided that any feedback is given prior to the tender close date in late 2011.

### **Key Dates and Timeframes for the 2011/12 Tender:**

The timelines for the 2011/12 Tender are envisaged to be similar to the 2010/11 Tender; we propose to release the final 2011/12 Invitation to Tender in early November 2011 and consequently the closing date for tender submissions would be late December 2011. The proposed timeline is outlined in the following table:

Date	Event
11 July 2011	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
05 August 2011	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
19 August 2011	Final date for all consultation to be received.
05 September 2011	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September 2011	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2011	Consultation and Board decisions on Alternative Commercial Proposals.
Early November 2011	Issuing of the 2011/12 Invitation to Tender.
21 December 2011	Invitation to Tender closes.
From end of January 2012	Board decisions on the first Tender winners announced.

### Unresolved Tender Bids

We intend to review any unresolved Tender Bids from the 2009/10 Tender and the 2010/11 Tender prior to issuing the 2011/12 Tender.

Should any unresolved Tender Bids be declined prior to the release of the 2011/12 Tender, PHARMAC would consider re-tendering those pharmaceuticals when the 2011/12 Tender is issued. Unresolved Tender Bids have not been included in the draft pharmaceutical list (Schedule Two).

### Products not currently listed on the Pharmaceutical Schedule

The following products included in Schedule Two of the draft 2011/12 Tender are not currently listed on the Pharmaceutical Schedule:

- Aciclovir cream 5% #
- Bimatoprost with timolol eye drops 0.03% with timolol 0.5%
- Granisetron tab 1 mg
- Indomethacin cap 25 mg #
- Indomethacin cap 50 mg #
- Indomethacin cap long-acting 75 mg #
- Latanoprost with timolol eye drops 50 mcg per ml with timolol 0.5%
- L-Cartinine tab 300 mg – 500 mg
- L-Cartinine oral liq 500 mg per 15 ml
- L-Cartinine powder
- L-Cartinine inj 200 mg per ml
- Nitrofurantoin oral liq 25 mg per 5 ml #
- Nortriptyline hydrochloride oral liq 10 mg per 5 ml #
- Phenobarbitone oral liq 15 mg per 5 ml #
- Pipobroman tab 25 mg \*
- Travoprost with timolol eye drops 0.004% with timolol 0.5%

Products marked with an "\*" have been considered for funding by the Pharmacology and Therapeutic Advisory Committee (PTAC) or the relevant Subcommittee of PTAC; however, these products, and the remainder of the chemicals in the list above, may be considered further by PTAC and/or its Subcommittees after tender bids have been received.

Products marked with an “#” have been listed on the Pharmaceutical Schedule previously.

### **Electronic Tender (eTender) system**

The 2011/12 Invitation to Tender will be distributed via PHARMAC’s eTender system. Please let us know by **5pm, 30 September 2011** if the contact details for the person responsible for submitting tender bids have changed for your company or if you would like to register your company to use the eTender system.

### **Material changes to the 2011/12 Tender**

The following changes are proposed to the 2011/12 Tender:

#### *ACP consultation*

We are proposing that in future we will generally not include pricing information in consultation on ACPs, instead providing an indication of the direction and magnitude of any price changes. This would apply only to consultation on products which have been included in the draft tender list or would potentially be added to the 2011/12 Tender. Pricing would be included in any notification documents prior to implementation through the Pharmaceutical Schedule.

While historically we have included pricing information in consultation documents, we consider that it may generally be appropriate to exclude this information from consultation on tender products in future. This would ensure that a supplier’s pricing would not have been exposed prior to tendering if we ultimately declined an ACP following consultation.

#### *Tender items subject to Special Authority criteria*

We are proposing to allow bids for both the current access criteria and for widened access criteria (e.g. with no Special Authority (SA) criteria) for some products currently subject to SA restrictions.

In previous tenders suppliers have indicated that they may be able to offer better pricing if they have certainty that SA criteria would be removed following a tender being awarded. Allowing bids for both levels of access would mean that suppliers would be able to offer their best pricing for both access levels.

If we did proceed with this approach in the 2011/12 Tender, only one option would be awarded (i.e. for either the current access criteria or widened access criteria), although, PHARMAC would retain the discretion to subsequently widen access at a later date if the tender were awarded for the current access criteria. The removal of SA criteria may be subject to PHARMAC taking clinical advice on the appropriateness of removing criteria.

Products that we are considering allowing bids under both the current access criteria and widened access criteria are capecitabine, irinotecan and vinorelbine, included in Schedule Two of the draft 2011/12 Tender.

#### *Additional Stock Pharmaceuticals*

We are proposing to designate a small number of pharmaceuticals “Additional Stock Pharmaceuticals” (ASPs). ASPs would be subject to the same terms and conditions as other tender products, but would have enhanced stock holding requirements whereby suppliers

would be required to hold a minimum of 4 months stock at any time, and to notify PHARMAC at any time that stock falls below this level. This is likely to include amoxicillin clavulanate tablets and oral liquids, roxithromycin tablets, erythromycin oral liquids, benzathine benzylpenicillin injection and other products as necessary.

To help address any concerns around excess stock at the end of the tender period, PHARMAC proposes to ensure that there would be at least four months notice of implementation of any subsequent listing decision where such a decision would result in a brand switch.

ASPs would be identified in the tender document with "ASP" in the comments field and additional stock requirements would be detailed through amendments to existing definitions, terms and conditions in the 2011/12 Tender.

#### *Amendment to Clause 1.1 (b) of Schedule 5*

We propose to amend Clause 1.1 (b) of Schedule 5 as shown below (addition in bold):

"The subsidy payable for all other brands of that form and strength of the Chemical Entity that are listed will be changed to the Price on the first day of the Second Transition Period, **unless the Price exceeds the subsidy applicable to it immediately prior to the First Transition Period, in which case the subsidy will remain unchanged.**"

This clause would be applicable where a tender is awarded to an alternative brand, usually resulting in reference pricing of the current listed brand. In accordance with the proposed wording we would not increase the subsidy on the listed brand following another brand being listed at a higher price.

#### **Alternative Commercial Proposals**

PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit. An ACP may, for example, offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period.

Please note the following points apply to ACPs for both the community and DHB hospital markets:

- ACPs may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft 2011/12 Tender;
- ACPs may seek PHARMAC's agreement to defer tendering or application of reference pricing for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft 2011/12 Tender;
- ACPs may propose PHARMAC awarding Hospital Supply Status for Hospital Pharmaceuticals included in Schedule Two but may not propose awarding Sole Subsidised Supply Status in the community;
- PHARMAC reserves the right:
  - not to accept any ACP; and/or
  - not to provide reasons for the acceptance or non-acceptance of any ACP; and/or

- to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter; and

ACPs are due by **5pm, Friday 5 August 2011**. PHARMAC may not consider any ACPs that are submitted after this date.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Acarbose</b>						
<u>Tab 50 mg</u>	1,349,106	\$247,336	\$0.1833	C H	1%	
<u>Tab 100 mg</u>	419,055	\$124,320	\$0.2967	C H	1%	
<b>Aciclovir</b>						
Cream 5%				C H	1%	Not currently listed on the Pharmaceutical Schedule
<u>Inj 250 mg</u>				H	1%	
<b>Alprostadil</b>						
<u>Inj 0.5 mg per ml, 1 ml</u>				H	1%	
<b>Amoxicillin</b>						
Grans for oral liq 125 mg per 5 ml	29,649,920	\$459,574	\$0.0155	C H	1%	
<u>Grans for oral liq 250 mg per 5 ml</u>	28,276,430	\$311,041	\$0.0110	C H	1%	
<b>Amoxicillin Clavulanate</b>						
<u>Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml</u>	10,232,449	\$225,114	\$0.0220	C H	1%	ASP
<u>Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml</u>	15,452,855	\$594,935	\$0.0385	C H	1%	ASP
<u>Inj 600 mg</u>				H	1%	
<u>Inj 1.2 g</u>				H	1%	
<b>Amphotericin B</b>						
<u>Liposomal inj 50 mg</u>				H	1%	
<b>Aripiprazole</b>						
Tab 10 mg				H	1%	
Tab 15 mg				H	1%	
Tab 20 mg				H	1%	
Tab 30 mg				H	1%	
<b>Atenolol</b>						
<u>Tab 50 mg</u>	6,949,334	\$85,894	\$0.0124	C H	1%	
<u>Tab 100 mg</u>	2,704,806	\$58,045	\$0.0215	C H	1%	
<b>Atorvastatin</b>						
Tab 10 mg	8,169,186	\$4,988,650	\$0.6107	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Tab 20 mg	13,404,512	\$11,930,016	\$0.8900	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Tab 40 mg	13,912,170	\$17,167,618	\$1.2340	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Atorvastatin</b>							
Tab 80 mg	1,985,589	\$7,313,586	\$3.6833	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.	
<b>Atracurium Besylate</b>							
<u>Inj 10 mg per ml. 2.5 ml</u>				H	1%		
<u>Inj 10 mg per ml. 5 ml</u>				H	1%		
<b>Atropine Sulphate</b>							
<u>Inj 600 mcg. 1 ml</u>	64,736	\$67,325	\$1.0400	C H	1%		
<b>Azithromycin</b>							
<u>Tab 500 mg</u>	107,799	\$320,702	\$2.9750	C H	1%		
<b>Baclofen</b>							
<u>Inj 10 mg</u>				H	1%		
<u>Tab 10 mg</u>	3,602,772	\$171,132	\$0.0475	C H	1%		
<b>Benzathine Benzylpenicillin</b>							
Inj 1.2 mega u	7,200	\$226,800	\$31.5000	C H	1%	ASP	
<b>Betamethasone Valerate</b>							
<u>Scalp app 0.1%</u>	2,894,313	\$208,969	\$0.0722	C H	1%		
<b>Bezafibrate</b>							
Tab 200 mg	1,161,894	\$125,872	\$0.1083	C H	1%		
Tab long-acting 400 mg	6,349,031	\$1,206,316	\$0.1900	C H	1%		
<b>Bimatoprost</b>							
Eye Drops 0.03%	202,675	\$1,317,388	\$6.5000	C H	1%		
<b>Bimatoprost with timolol</b>							
Eye Drops 0.03% with timolol 0.5%				+ C H	1%	Not currently listed on the Pharmaceutical Schedule	
<b>Brinzolamide</b>							
Eye Drops 1%	189,629	\$370,535	\$1.9540	C H	1%		
<b>Bupivacaine Hydrochloride</b>							
<u>Inj 0.25%. 20 ml</u>				H	1%		
<u>Inj 0.5%. 10 ml</u>				H	1%		
<u>Inj 0.5%. 10 ml theatre pack</u>				H	1%		
<u>Inj 0.5%. 20 ml theatre pack</u>				H	1%		
<b>Cabergoline</b>							
Tab 0.5 mg	62,400	\$514,800	\$8.2500	C H	1%		
<b>Calamine</b>							
<u>Crm. aqueous. BP</u>	902,615	\$25,093	\$0.0278	C H	1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Calamine</b>						
<u>Lotn. BP</u>	5,205,621	\$43,467	\$0.0084	C H	1%	
<b>Calcipotriol</b>						
Crn 50 mcg per g (pack size 30 g or less)	42,780	\$28,805	\$0.6733	C H	1%	
Crn 50 mcg per g (pack size greater than 30 g)	1,458,700	\$821,540	\$0.5632	C H	1%	
Oint 50 mcg per g (pack size 30 g or less)	40,620	\$27,351	\$0.6733	C H	1%	
Oint 50 mcg per g (pack size greater than 30 g)	1,436,400	\$808,980	\$0.5632	C H	1%	
Soln 50 mcg per ml (pack size 30 ml or less)	43,080	\$29,036	\$0.6740	C H	1%	
Soln 50 mcg per ml (pack size greater than 30 ml)	238,140	\$134,113	\$0.5632	C H	1%	
<b>Calcitriol</b>						
<u>Cap 0.25 mcg</u>	1,992,104	\$201,203	\$0.1010	C H	1%	
<u>Cap 0.5 mcg</u>	462,894	\$86,715	\$0.1873	C H	1%	
<b>Capecitabine (current access)</b>						
Tab 150 mg	688,630	\$4,045,701	\$5.8750	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
Tab 500 mg	110,540	\$211,868	\$1.9167	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
<b>Capecitabine (widened access)</b>						
Tab 150 mg	688,630	\$4,045,701	\$5.8750	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
Tab 500 mg	110,540	\$211,872	\$1.9167	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
<b>Carboplatin</b>						
<u>Inj 10 mg per ml, 5 ml</u>				H PCT	1%	
<u>Inj 10 mg per ml, 15 ml</u>				H PCT	1%	
<u>Inj 10 mg per ml, 45 ml</u>				H PCT	1%	
<u>Inj 10 mg per ml, 100 ml</u>				H PCT	1%	
<b>Caspofungin</b>						
<u>Inj 50 mg</u>				H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Caspofungin</b>						
<u>Inj 70 mg</u>					H 1%	
<b>Cephalexin Monohydrate</b>						
<u>Grans for oral liq 125 mg per 5 ml</u>	151,572	\$12,884	\$0.0850		C H 1%	
<u>Grans for oral liq 250 mg per 5 ml</u>	293,319	\$33,732	\$0.1150		C H 1%	
<b>Chloramphenicol</b>						
<u>Eye drops 0.5%</u>	1,898,902	\$243,059	\$0.1280		C H 1%	Single dose presentation would not be a DV Pharmaceutical
<u>Eye oint 1%</u>	555,492	\$329,129	\$0.5925		C H 1%	
<b>Chlorhexidine</b>						
<u>Crn 1% obstetric</u>					H 1%	
<b>Chlorhexidine Gluconate</b>						
<u>Handrub 0.5% - 1% with ethanol 70%</u>	2,389,438	\$21,983	\$0.0092		C	Chlorhexidine strengths from 0.5% to 1% would be considered
<u>Mouthwash 0.2%</u>	2,596,854	\$50,249	\$0.0194		C H 1%	
<b>Cholecalciferol</b>						
<u>Tab 1.25 mg (50,000 iu)</u>	2,015,516	\$1,303,367	\$0.6467		C H 1%	
<b>Ciclopiroxolamine</b>						
<u>Nail soln 8%</u>	80,403	\$456,000	\$5.6714		C	
<b>Clobetasol Propionate</b>						
<u>Crn 0.05% (pack size 30 g or less)</u>	2,781,830	\$322,692	\$0.1160		C H 1%	
<u>Oint 0.05% (pack size 30 g or less)</u>	2,779,609	\$322,435	\$0.1160		C H 1%	
<u>Scalp app 0.05%</u>	578,567	\$122,656	\$0.2120		C H 1%	
<b>Clomipramine Hydrochloride</b>						
<u>Tab 10 mg</u>	302,166	\$38,073	\$0.1260		C H 1%	
<u>Tab 25 mg</u>	1,883,291	\$163,470	\$0.0868		C H 1%	
<b>Clonidine</b>						
<u>Inj 150 mcg per ml, 1 ml</u>	10,798	\$33,366	\$3.0900		C H 1%	
<u>Tab 25 mcg</u>	2,654,960	\$511,080	\$0.1925		C H 1%	
<u>Tab 150 mcg</u>	539,110	\$177,906	\$0.3300		C H 1%	
<u>TDSS 2.5 mg, 100 mcg per day</u>	46,088	\$268,463	\$5.8250		C H 1%	
<u>TDSS 5 mg, 200 mcg per day</u>	13,059	\$107,084	\$8.2000		C H 1%	
<u>TDSS 7.5 mg, 300 mcg per day</u>	9,436	\$97,191	\$10.3000		C H 1%	
<b>Codeine Phosphate</b>						
<u>Tab 15 mg</u>	5,434,686	\$292,930	\$0.0539		C H 1%	A tender would not be implemented prior to November 2012

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Codeine Phosphate</b>							
Tab 30 mg	20,111,116	\$1,659,167	\$0.0825	C H	1%	A tender would not be implemented prior to November 2012	
Tab 60 mg	1,942,316	\$344,955	\$0.1776	C H	1%	A tender would not be implemented prior to November 2012	
<b>Co-Trimoxazole</b>							
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,324,816	\$113,044	\$0.0340	C H	1%		
<b>Crotamiton</b>							
<u>Crm 10%</u>	560,138	\$106,146	\$0.1895	C H	1%		
<b>Cyclizine Hydrochloride</b>							
<u>Tab 50 mg</u>	1,155,093	\$183,660	\$0.1590	C H	1%		
<b>Cyclosporin</b>							
Cap 25 mg	1,170,509	\$1,392,906	\$1.1900	C H	1%	Bids would need to be for a microemulsion formulation.	
Cap 50 mg	384,922	\$912,573	\$2.3708	C H	1%	Bids would need to be for a microemulsion formulation.	
Cap 100 mg	546,590	\$2,591,711	\$4.7416	C H	1%	Bids would need to be for a microemulsion formulation.	
<u>Inf 50 mg per ml, 5 ml</u>				H	1%		
Oral liq 100 mg per ml	18,432	\$97,384	\$5.2834	C H	1%		
<b>Cyproterone Acetate</b>							
<u>Tab 50 mg</u>	805,460	\$339,904	\$0.4220	C H	1%		
<u>Tab 100 mg</u>	35,188	\$29,206	\$0.8300	C H	1%		
<b>Dexamethasone</b>							
Tab 0.5 mg - 1 mg	419,267	\$67,418	\$0.1608	C H	1%	1 mg tablet units and subsidy shown. A 0.5 mg tablet is not currently listed in the Pharmaceutical Schedule.	
Tab 4 mg	791,534	\$489,880	\$0.6189	C H	1%		
<b>Dexamphetamine Sulphate</b>							
Tab 5 mg	641,809	\$105,898	\$0.1650	C H	1%	A tender would not be implemented prior to November 2012	
<b>Diclofenac Sodium</b>							
<u>Tab EC 25 mg</u>	611,472	\$19,934	\$0.0326	C H	1%		
<u>Tab EC 50 mg</u>	4,541,303	\$193,460	\$0.0426	C H	1%		
Tab long-acting 75 mg	23,324,952	\$1,530,117	\$0.0656	C H	1%		
Tab long-acting 100 mg	3,455,177	\$436,873	\$0.1264	C H	1%		
<b>Diltiazem Hydrochloride</b>							
Tab 30 mg	641,943	\$29,529	\$0.0460	C H	1%		
Tab 60 mg	365,906	\$31,102	\$0.0850	C H	1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Diltiazem Hydrochloride</b>						
Cap long-acting 120 mg	8,735,834	\$1,264,075	\$0.1447	C H	1%	
Cap long-acting 180 mg	7,447,403	\$1,613,852	\$0.2167	C H	1%	
Cap long-acting 240 mg	5,283,655	\$1,526,976	\$0.2890	C H	1%	
<b>Donepezil hydrochloride</b>						
<u>Tab 5 mg</u>	639,394	\$54,775	\$0.0857	C H	1%	Recently listed on Pharmaceutical Schedule
<u>Tab 10 mg</u>	651,151	\$101,724	\$0.1562	C H	1%	Recently listed on Pharmaceutical Schedule
<b>Dopamine</b>						
<u>Inj 40 mg per ml, 5 ml</u>				H	1%	
<b>Doxepin Hydrochloride</b>						
Cap 10 mg	1,660,537	\$87,012	\$0.0524	C H	1%	A tender would not be implemented until at least November 2012.
Cap 25 mg	2,238,223	\$122,207	\$0.0546	C H	1%	A tender would not be implemented until at least November 2012.
Cap 50 mg	932,297	\$68,431	\$0.0734	C H	1%	A tender would not be implemented until at least November 2012.
Cap 75 mg				C H	1%	Not currently listed. A tender would not be implemented until at least November 2012.
<b>Doxorubicin</b>						
<u>Inj 10 mg</u>				H PCT	1%	
<u>Inj 50 mg</u>				H PCT	1%	
<u>Inj 100 mg</u>				H PCT	1%	
<u>Inj 200 mg</u>				H PCT	1%	
<b>Efavirenz</b>						
Cap 50 mg				+ C H	1%	
Cap 100 mg				+ C H	1%	
Cap 200 mg				+ C H	1%	
Tab 50 mg	2,738	\$14,450	\$5.2777	+ C H	1%	
Tab 200 mg	2,088	\$11,020	\$5.2777	+ C H	1%	
Tab 600 mg	228,554	\$3,618,695	\$15.8330	+ C H	1%	
<b>Emtricitabine</b>						
Cap 200 mg	245,880	\$2,517,811	\$10.2400	+ C H	1%	
<b>Enalapril</b>						
<u>Tab 5 mg</u>	3,562,631	\$78,378	\$0.0220	C H	1%	
<u>Tab 10 mg</u>	3,524,700	\$95,559	\$0.0271	C H	1%	
<u>Tab 20 mg</u>	3,394,992	\$122,220	\$0.0360	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>	
<b>Enoxaparin Sodium</b>						
<u>Inj 20 mg per 0.2 ml</u>	6,812	\$26,703	\$3.9200	C H	1%	
<u>Inj 40 mg per 0.4 ml</u>	70,735	\$369,944	\$5.2300	C H	1%	
<u>Inj 60 mg per 0.6 ml</u>	28,422	\$224,107	\$7.8850	C H	1%	
<u>Inj 80 mg per 0.8 ml</u>	44,855	\$471,516	\$10.5120	C H	1%	
<u>Inj 100 mg per ml, 1 ml</u>	58,482	\$790,677	\$13.5200	C H	1%	
<u>Inj 120 mg per 0.8 ml</u>	35,337	\$593,662	\$16.8000	C H	1%	
<u>Inj 150 mg per ml, 1 ml</u>	21,582	\$414,374	\$19.2000	C H	1%	
<b>Entacapone</b>						
<u>Tab 200 mg</u>	690,619	\$801,118	\$1.1600	C H	1%	
<b>Epirubicin</b>						
<u>Inj 2 mg per ml, 5 ml</u>				H PCT	1%	
<u>Inj 2 mg per ml, 25 ml</u>				H PCT	1%	
<u>Inj 2 mg per ml, 50 ml</u>				H PCT	1%	
<u>Inj 2 mg per ml, 100 ml</u>				H PCT	1%	
<b>Erythromycin Ethyl Succinate</b>						
Grans for oral liq 200 mg per 5 ml	7,069,230	\$307,512	\$0.0435	C H	1%	ASP
Grans for oral liq 400 mg per 5 ml	4,483,547	\$262,287	\$0.0585	C H	1%	ASP
<u>Tab 400 mg</u>	4,871,360	\$825,696	\$0.1695	C H	1%	
<b>Ethinylestradiol</b>						
<u>Tab 10 mcg</u>	363,573	\$63,989	\$0.1760	C		
<b>Etidronate Disodium</b>						
<u>Tab 200 mg</u>	1,117,632	\$267,673	\$0.2395	C H	1%	
<b>Felodipine</b>						
Tab long-acting 2.5 mg	9,453,744	\$3,270,995	\$0.3460	C H	1%	
<u>Tab long-acting 5 mg</u>	15,941,345	\$1,900,563	\$0.1192	C H	1%	
<u>Tab long-acting 10 mg</u>	11,509,413	\$1,994,965	\$0.1733	C H	1%	
<b>Fentanyl</b>						
<u>Inj 50 mcg per ml, 2 ml</u>	73,463	\$47,237	\$0.6430	C H	1%	
<u>Inj 50 mcg per ml, 10 ml</u>	11,424	\$19,204	\$1.6810	C H	1%	
<b>Flucloxacillin</b>						
<u>Grans for oral liq 125 mg per 5 ml</u>	6,209,212	\$193,727	\$0.0312	C H	1%	Bids would be accepted for either the sodium or magnesium salts
<u>Grans for oral liq 250 mg per 5 ml</u>	7,735,625	\$274,615	\$0.0355	C H	1%	Bids would be accepted for either the sodium or magnesium salts

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Flucloxacillin Sodium</b>						
<u>Cap 250 mg</u>	1,593,425	\$203,958	\$0.1280	C H	1%	
<u>Cap 500 mg</u>	11,035,657	\$2,427,845	\$0.2200	C H	1%	
<b>Fluconazole</b>						
<u>Inj 2 mg per ml, 50 ml</u>				H	1%	
<b>Fluorometholone</b>						
<u>Eye drops 0.1%</u>	57,213	\$46,343	\$0.8100	C H	1%	
<b>Fluorouracil Sodium</b>						
Crm 5%	554,491	\$734,423	\$1.3245	C H	1%	A tender would not be implemented prior to October 2012
<b>Fluticasone propionate</b>						
Metered aqueous nasal spray, 50 mcg per dose	28,026,549	\$3,115,618	\$0.1112	C H	1%	A confidential rebate currently exists. A tender would not be implemented prior to December 2012
<b>Furosemide</b>						
<u>Tab 40 mg</u>	36,605,391	\$393,508	\$0.0108	C H	1%	
Tab 500 mg	246,100	\$123,050	\$0.5000	C H	1%	
<b>Gentamicin Sulphate</b>						
<u>Inj 40 mg per ml, 2 ml</u>	5,153	\$4,638	\$0.9000	C H	1%	
<b>Gestrinone</b>						
Cap 2.5 mg	4,575	\$58,257	\$12.7338	C H	1%	
<b>Glipizide</b>						
Tab 5 mg	14,523,763	\$508,332	\$0.0350	C H	1%	
<b>Glycerol</b>						
Suppos greater than 3 g	223,766	\$67,130	\$0.3000	C H	1%	
<b>Glyceryl Trinitrate</b>						
<u>Inj 1 mg per ml, 5 ml</u>				H	1%	
<u>Inj 1 mg per ml, 50 ml</u>				H	1%	
Inj 5 mg per ml, 10 ml				H	1%	
<b>Granisetron</b>						
Tab 1 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Heparin Sodium</b>						
Inj 100 iu per ml, 250 ml				H	1%	
<b>Heparinised Saline</b>						
Inj 100 iu per ml, 2 ml ampoule				H	1%	
Inj 100 iu per ml, 5 ml ampoule				H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Hydrocortisone</b>						
<u>Tab 5 mg</u>	2,874,266	\$240,001	\$0.0835	C H	1%	
<u>Tab 20 mg</u>	133,427	\$27,953	\$0.2095	C H	1%	
<b>Hydrocortisone Acetate</b>						
<u>Rectal foam 10%, CFC-free</u>	206,440	\$225,029	\$1.0900	C H	1%	
<b>Hydrocortisone Butyrate</b>						
Lipocream 0.1% (pack size 30 g or less)	1,979,340	\$151,749	\$0.0767	C H	1%	A tender would not be implemented prior to November 2012
Lipocream 0.1% (pack size greater than 30 g)	17,313,700	\$1,327,384	\$0.0767	C H	1%	A tender would not be implemented prior to November 2012
Milky Emulsion 0.1% (pack size 30 g or less)				C H	1%	Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012.
Milky Emulsion 0.1% (pack size greater than 30 g)	1,598,597	\$109,504	\$0.0685	C H	1%	A tender would not be implemented prior to November 2012
Oint 0.1% (pack size 30 g or less)				C H	1%	Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012.
Oint 0.1% (pack size greater than 30 g)	1,938,341	\$132,776	\$0.0685	C H	1%	A tender would not be implemented prior to November 2012
Scalp lotn 0.1%	3,598,370	\$131,341	\$0.0365	C H	1%	A tender would not be implemented prior to November 2012
<b>Hydrocortisone with Natamycin and Neomycin</b>						
Crn 1% with natamycin 1% and neomycin sulphate 0.5%	2,302,991	\$428,356	\$0.1860	C H	1%	A tender would not be implemented prior to November 2012
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	848,073	\$157,742	\$0.1860	C H	1%	A tender would not be implemented prior to November 2012
<b>Hydroxocobalamin</b>						
<u>Inj 1 mg per ml, 1 ml</u>	260,669	\$534,371	\$2.0500	C H	1%	
<b>Hydroxychloroquine Sulphate</b>						
<u>Tab 200 mg</u>	2,860,868	\$643,695	\$0.2250	C H	1%	
<b>Hydroxyethyl Starch 130/0.4</b>						
<u>Inj 6%</u>				H	1%	
<b>Hydroxyethyl Starch 200/0.5</b>						
<u>Inj 6%</u>				H	1%	
<b>Idarubicin Hydrochloride</b>						
<u>Cap 5 mg</u>				H	PCT 1%	
<u>Cap 10 mg</u>				H	PCT 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>								
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>		
<b>Idarubicin Hydrochloride</b>								
<u>Inj 5 mg</u>					H PCT 1%			
<u>Inj 10 mg</u>					H PCT 1%			
<b>Imatinib Mesylate</b>								
Tab 100 mg	469,635	\$18,785,400	\$40.0000	+ C H	1%	Bids would be accepted for either tablets or capsules. Tender agreement may be subject to a Special Authority restriction		
<b>Indomethacin</b>								
Cap 25 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule		
Cap 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule		
Cap long-acting 75 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule		
<b>Intra-Uterine Device</b>								
IUD - Short length	6,514	\$257,303	\$39.5000	C H	1%	Units aggregated for both lengths		
IUD - Standard length	6,514	\$257,303	\$39.5000	C H	1%	Units aggregated for both lengths		
<b>Irinotecan (current access)</b>								
<u>Inj 20 mg per ml, 2 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.		
<u>Inj 20 mg per ml, 5 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.		
<b>Irinotecan (widened access)</b>								
<u>Inj 20 mg per ml, 2 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.		
<u>Inj 20 mg per ml, 5 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.		
<b>Isoniazid</b>								
Tab 100 mg	240,528	\$48,106	\$0.2000	C H	1%	A tender would not be implemented prior to November 2012		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Isotretinoin</b>							
<u>Cap 10 mg</u>	1,340,876	\$361,143	\$0.2693	C H	1%	Information on appropriate use should be available on a website	
<u>Cap 20 mg</u>	1,403,423	\$543,437	\$0.3872	C H	1%	Information on appropriate use should be available on a website	
<b>Lansoprazole</b>							
Cap 15 mg	1,138,500	\$142,313	\$0.1250	C H	1%	A tender would not be implemented prior to September 2012	
Cap 30 mg	3,049,230	\$506,390	\$0.1661	C H	1%	A tender would not be implemented prior to September 2012	
<b>Latanoprost</b>							
<u>Eye drops 50 mcg per ml</u>	586,590	\$2,287,701	\$3.9000	C H	1%		
<b>Latanoprost with timolol</b>							
Eye drops 50 mcg per ml with timolol 0.5%				+ C H	1%	Not currently listed on the Pharmaceutical Schedule	
<b>L-Carnitine</b>							
Inj 200 mg per ml				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.	
Oral liquid 500 mg per 15 ml				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.	
Powder				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.	
Tab 300 mg - 500 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.	
<b>Letrozole</b>							
<u>Tab 2.5 mg</u>	478,088	\$423,108	\$0.8850	C H	1%		
<b>Lignocaine</b>							
<u>Gel 2%</u>				H	1%		
<b>Lignocaine Hydrochloride</b>							
<u>Inj 1%, 2 ml</u>				H	1%		
<u>Inj 1%, 5 ml</u>				H	1%		
<u>Inj 1%, 20 ml</u>				H	1%		
<u>Inj 2%, 2 ml</u>				H	1%		
<u>Inj 2%, 5 ml</u>				H	1%		
<u>Inj 2%, 20 ml</u>				H	1%		
<b>Lisinopril</b>							
<u>Tab 5 mg</u>	823,657	\$56,558	\$0.0687	C H	1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>	
<b>Lisinopril</b>						
<u>Tab 10 mg</u>	887,820	\$69,842	\$0.0787	C H	1%	
<u>Tab 20 mg</u>	1,199,797	\$114,781	\$0.0957	C H	1%	
<b>Lithium Carbonate</b>						
Tab 250 mg	1,946,246	\$140,519	\$0.0722	C H	1%	
Tab 400 mg	289,100	\$39,029	\$0.1350	C H	1%	
Tab long-acting 400 mg	1,282,514	\$237,265	\$0.1850	C H	1%	
<b>Megestrol Acetate</b>						
<u>Tab 160 mg</u>	44,413	\$85,747	\$1.9307	C H	1%	
<b>Mesalazine</b>						
<u>Enema 1 g per 100 ml</u>	54,805	\$359,834	\$6.5657	C H	1%	
Tab EC 500 mg	148,439	\$73,477	\$0.4950	C H	1%	
<b>Metformin Hydrochloride</b>						
<u>Tab immediate-release 500 mg</u>	91,290,791	\$1,477,085	\$0.0162	C H	1%	
<u>Tab immediate-release 850 mg</u>	16,607,503	\$443,088	\$0.0267	C H	1%	
<b>Methadone Hydrochloride</b>						
<u>Oral liq 2 mg per ml</u>	1,852,661	\$55,117	\$0.0298	C H	1%	
<u>Oral liq 5 mg per ml</u>	23,246,976	\$645,104	\$0.0278	C H	1%	
<u>Oral liq 10 mg per ml</u>	3,408,625	\$152,536	\$0.0448	C H	1%	
<b>Methotrexate</b>						
<u>Tab 2.5 mg</u>	1,999,584	\$347,928	\$0.1740	C H	1%	
<u>Tab 10 mg</u>	456,729	\$373,878	\$0.8186	C H	1%	
<b>Methylprednisolone</b>						
<u>Tab 4 mg</u>	31,408	\$15,255	\$0.4857	C H	1%	
<u>Tab 100 mg</u>	22,794	\$189,783	\$8.3260	C H	1%	
<b>Methylprednisolone Acetate</b>						
Inj 40 mg per ml, 1 ml	5,870	\$35,396	\$6.0300	C H	1%	
<b>Methylprednisolone Acetate with Lignocaine</b>						
Inj 40 mg per ml with lignocaine 1 ml	2,148	\$12,952	\$6.0300	C H	1%	
<b>Methylprednisolone Sodium Succinate</b>						
<u>Inj 40 mg per ml, 1 ml</u>	509	\$3,083	\$6.0560	C H	1%	
<u>Inj 62.5 mg per ml, 2 ml</u>	687	\$11,338	\$16.5036	C H	1%	
<u>Inj 500 mg</u>	128	\$2,662	\$20.8000	C H	1%	
<u>Inj 1 g</u>	71	\$3,022	\$42.5700	C H	1%	
<b>Miconazole</b>						
Oral gel 20 mg per g	637,292	\$138,611	\$0.2175	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Mirtazapine</b>						
Tab 15 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 30 mg	629,445	\$461,572	\$0.7333	C H	1%	
Tab 45 mg	131,842	\$153,807	\$1.1666	C H	1%	
<b>Moclobemide</b>						
Tab 150 mg	1,322,067	\$183,053	\$0.1385	C H	1%	
Tab 300 mg	396,647	\$124,270	\$0.3133	C H	1%	
<b>Mometasone Furoate</b>						
Crn 0.1% (pack size 30 g or less)	280,315	\$44,477	\$0.1587	C H	1%	
Crn 0.1% (pack size greater than 30 g)	2,810,260	\$445,895	\$0.1587	C H	1%	
Oint 0.1% (pack size 30 g or less)	173,760	\$27,570	\$0.1587	C H	1%	
Oint 0.1% (pack size greater than 30 g)	1,940,106	\$307,830	\$0.1587	C H	1%	
<b>Morphine Hydrochloride</b>						
Oral liq 1 mg per ml	5,986,436	\$264,600	\$0.0442	C H	1%	
Oral liq 2 mg per ml	683,564	\$39,715	\$0.0581	C H	1%	
Oral liq 5 mg per ml	823,661	\$60,333	\$0.0733	C H	1%	
Oral liq 10 mg per ml	557,546	\$60,076	\$0.1078	C H	1%	
<b>Morphine Sulphate</b>						
Tab immediate release 10 mg	1,556,437	\$435,802	\$0.2800	C H	1%	
Tab immediate release 20 mg	678,780	\$374,687	\$0.5520	C H	1%	
<b>Mycophenolate Mofetil</b>						
Cap 250 mg	538,432	\$457,667	\$0.8500	C H	1%	
Inj 500 mg				H	1%	
Powder for oral liq 1 g per 5 ml	34,215	\$59,099	\$1.7273	C H	1%	
Tab 500 mg	860,272	\$1,462,462	\$1.7000	C H	1%	
<b>Nadolol</b>						
Tab 40 mg	1,962,348	\$293,763	\$0.1497	C H	1%	
Tab 80 mg	620,894	\$137,776	\$0.2219	C H	1%	
<b>Naproxen</b>						
Tab 250 mg	1,933,579	\$91,652	\$0.0474	C H	1%	
Tab 500 mg	4,364,536	\$434,359	\$0.0995	C H	1%	
<b>Nevirapine</b>						
Oral suspension 10 mg per ml	10,993	\$6,163	\$0.5606	C H	1%	
Tab 200 mg	167,750	\$894,108	\$5.3300	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Nitrofurantoin</b>						
Oral liq 25 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 50 mg	1,795,060	\$398,503	\$0.2220	C H	1%	
Tab 100 mg	566,769	\$212,538	\$0.3750	C H	1%	
<b>Norethisterone</b>						
<u>Tab 350 mcg</u>	10,338,814	\$880,030	\$0.0851	C		
<b>Nortriptyline hydrochloride</b>						
Oral liq 10 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 10 mg	6,550,532	\$389,102	\$0.0594	C H	1%	
Tab 25 mg	8,297,885	\$665,675	\$0.0802	C H	1%	
<b>Octreotide (somatostatin analogue)</b>						
LAR inj 10 mg	200	\$354,500	\$1,772.5000	C H	1%	
LAR inj 20 mg	1,346	\$3,174,878	\$2,358.7500	C H	1%	
LAR inj 30 mg	996	\$2,939,445	\$2,951.2500	C H	1%	
<b>Oil in Water Emulsion</b>						
Crm	57,990,643	\$324,748	\$0.0056	C H	1%	A tender would not be implemented until at least 1 August 2012.
<b>Ondansetron Hydrochloride</b>						
<u>Inj 2 mg per ml, 2 ml</u>				H	1%	
<u>Inj 2 mg per ml, 4 ml</u>				H	1%	
<b>Oxaliplatin</b>						
<u>Inj 50 mg</u>				H PCT	1%	
<u>Inj 100 mg</u>				H PCT	1%	
<b>Oxycodone Hydrochloride</b>						
Cap 5 mg	1,986,372	\$281,072	\$0.1415	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.
Cap 10 mg	1,264,947	\$352,920	\$0.2790	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.
Cap 20 mg	531,908	\$259,837	\$0.4885	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.
Inj 10 mg per ml, 1 ml	35,454	\$102,108	\$2.8800	C H	1%	
Inj 10 mg per ml, 2 ml	53,872	\$310,303	\$5.7600	C H	1%	
Oral liq 5 mg per 5 ml	1,480,024	\$66,305	\$0.0448	C H	1%	
Tab controlled-release 5 mg	1,200,966	\$450,963	\$0.3755	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Oxycodone Hydrochloride</b>							
Tab controlled-release 10 mg	2,502,402	\$1,393,838	\$0.5570	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 20 mg	1,627,540	\$1,540,467	\$0.9465	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 40 mg	490,424	\$816,311	\$1.6645	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 80 mg	202,375	\$587,191	\$2.9015	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
<b>Oxytocin</b>							
<u>Inj 5 iu per ml, 1 ml</u>	858	\$1,019	\$1.1880	C H	1%		
<u>Inj 10 iu per ml, 1 ml</u>	5,035	\$7,532	\$1.4960	C H	1%		
<u>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml</u>	2,911	\$5,892	\$2.0240	C H	1%		
<b>Pancuronium bromide</b>							
<u>Inj 2 mg per ml, 2 ml</u>				H	1%		
<b>Paracetamol</b>							
Suppos 500 mg	128,785	\$52,802	\$0.4100	C H	1%	A tender would not be implemented prior to November 2012	
<b>Paraffin</b>							
<u>White soft or yellow soft (pack size 30 g or less)</u>				H	1%		
<b>Pethidine Hydrochloride</b>							
Tab 50 mg	244,205	\$78,146	\$0.3200	C H	1%	A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab 100 mg	94,432	\$39,661	\$0.4200	C H	1%	A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with child-resistant cap.	
<b>Phenobarbitone</b>							
Oral liq 15 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule. Alcohol free preparation preferred.	
Tab 15 mg	93,678	\$4,684	\$0.0500	C H	1%	A tender would not be implemented prior to November 2012	
Tab 30 mg	698,500	\$36,322	\$0.0520	C H	1%	A tender would not be implemented prior to November 2012	
<b>Phenobarbitone Sodium</b>							
Inj 200 mg per ml, 1 ml				H	1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Pholcodine</b>						
Oral liquid 1 mg per ml					H 1%	
<b>Pindolol</b>						
<u>Tab 5 mg</u>	227,995	\$12,312	\$0.0540		C H 1%	
<u>Tab 10 mg</u>	256,327	\$23,556	\$0.0919		C H 1%	
<u>Tab 15 mg</u>	105,971	\$14,624	\$0.1380		C H 1%	
<b>Pioglitazone</b>						
<u>Tab 15 mg</u>	544,130	\$50,721	\$0.0932		C H 1%	
<u>Tab 30 mg</u>	468,410	\$87,492	\$0.1868		C H 1%	
<u>Tab 45 mg</u>	400,807	\$111,653	\$0.2786		C H 1%	
<b>Pipobroman</b>						
Tab 25 mg					H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction.
<b>Pizotifen</b>						
<u>Tab 500 mcg</u>	1,357,566	\$286,446	\$0.2110		C H 1%	
<b>Potassium Chloride</b>						
<u>Tab long-acting 600 mg</u>	10,235,670	\$358,248	\$0.0350		C H 1%	
<b>Prednisolone Sodium Phosphate</b>						
<u>Oral liq 5 mg per ml</u>	3,865,171	\$1,281,948	\$0.3317		C H 1%	
<b>Pregnancy Tests - HCG Urine</b>						
<u>Urine diagnostic test</u>	425,767	\$242,687	\$0.5700		C H 1%	
<b>Promethazine Hydrochloride</b>						
<u>Oral liq 5 mg per 5 ml</u>	4,744,483	\$147,079	\$0.0310		C H 1%	
Tab 10 mg	1,536,704	\$83,597	\$0.0544		C H 1%	
Tab 25 mg	1,474,790	\$130,961	\$0.0888		C H 1%	
<b>Quinine Sulphate</b>						
<u>Tab 300 mg</u>	1,639,886	\$177,304	\$0.1081		C H 1%	
<b>Ritonavir</b>						
Cap 100 mg	90,389	\$130,494	\$1.4437	+ C H	1%	
Oral liq 80 mg per ml	0	\$0	\$1.1553	+ C H	1%	
<b>Rocuronium</b>						
<u>Inj 10 mg per ml, 5 ml</u>					H 1%	
<b>Roxithromycin</b>						
<u>Tab 150 mg</u>	2,511,083	\$450,991	\$0.1796		C H 1%	ASP
<u>Tab 300 mg</u>	941,935	\$310,462	\$0.3296		C H 1%	ASP

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Salbutamol</b>						
<u>Nebuliser soln, 1 mg per ml, 2.5 ml</u>	350,201	\$61,635	\$0.1760	C H	1%	
<u>Nebuliser soln, 2 mg per ml, 2.5 ml</u>	888,907	\$164,448	\$0.1850	C H	1%	
<b>Salbutamol with Ipratropium Bromide</b>						
<u>Nebuliser soln, 2.5 mg with ipratropium bromide, 0.5 mg per vial, 2.5 ml</u>	808,984	\$173,527	\$0.2145	C H	1%	
<b>Selegiline Hydrochloride</b>						
<u>Tab 5 mg</u>	190,971	\$30,670	\$0.1606	C		
<b>Sodium Cromoglycate</b>						
<u>Nasal spray, 4%</u>	59,247	\$42,685	\$0.7205	C		
<b>Sodium Hyaluronate</b>						
<u>Ophthalmic inj 14 mg per ml</u>				H	1%	
<u>Ophthalmic soln 10 mg per ml</u>				H	1%	
<b>Sotalol</b>						
<u>Tab 80 mg</u>	4,109,964	\$226,048	\$0.0550	C H	1%	
<u>Tab 160 mg</u>	358,745	\$37,668	\$0.1050	C H	1%	
<b>Testosterone Undecanoate</b>						
<u>Cap 40 mg</u>	884,574	\$706,952	\$0.7992	C H	1%	
<b>Thalidomide</b>						
Cap 50 mg				H PCT	1%	
Cap 100 mg				H PCT	1%	
<b>Theophylline</b>						
Oral liq 80 mg per 15 ml	95,919	\$2,973	\$0.0310	C H	1%	
Tab long-acting 250 mg	1,050,831	\$226,034	\$0.2151	C H	1%	
<b>Timolol Maleate</b>						
<u>Tab 10 mg</u>	138,978	\$14,662	\$0.1055	C H	1%	
<b>Tranexamic Acid</b>						
<u>Inj 100 mg per ml, 5 ml</u>				H	1%	
<b>Travoprost</b>						
Eye drops 0.004%	95,788	\$747,146	\$7.8000	C H	1%	
<b>Travoprost with timolol</b>						
Eye drops 0.004% with timolol 0.5%				+ C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Tropisetron</b>						
<u>Cap 5 mg</u>	2,041	\$31,599	\$15.4820	C H	1%	
Inj 1 mg per ml, 2 ml				H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED**

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Vinorelbine (current access)</b>						
<u>Inj 10 mg per ml, 1 ml</u>				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
<u>Inj 10 mg per ml, 5 ml</u>				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
<b>Vinorelbine (widened access)</b>						
Inj 10 mg per ml, 1 ml				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Inj 10 mg per ml, 5 ml				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
<b>Zoledronic Acid</b>						
Inj 4 mg				H 1%		